Profile:

ChanTest provides in vitro preclinical cardiac safety testing services (GLP and non-GLP) for hERG and other cardiac ion channels, action potential assays on stem cell-derived human cardiomyocytes and rabbit or canine Purkinje fibers, and isolated heart QT prolongation assays. The company offers the largest panel of ion channel targets for drug discovery and cardiac safety screening, and has been recognized as “the most trusted and most used ion channel services company” in independent surveys.